銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

A notable market event looms for the popular solar cell and module manufacturer Premier Energies as it will be completing the six-month lock-in period for a large number of its shares. A total of 106 million shares, 23% of the company’s outstanding equity, are now free to?trade. This?move should boost investor interest in Premier Energies.
On September?3, 2024, Premier Energies had an impressive stock market debut. The IPO was offered in a price band of ?427 to??450 per share. The stock debuted at??991 on the 娛樂城 (BSE), a premium of 120.22% on the issue price. On the National?贏家娛樂城 (NSE), too, the shares listed at ?990, up 120%. On its last day, the IPO received 74.09 times?more than its shares available. The ?28.3 billion IPO comprised a fresh issue of up to ?12.914 billion and an offer-for-sale of up to 34,200,000 equity shares
Premier Energies had planned to use ?9.686 billion from the fresh issue to fund investment in subsidiary?Premier Energies Global Environment Pvt Ltd. The investment will be used?to partially fund the construction of a 4 GW Solar PV TOPCon Cell and 4 GW Solar PV TOPCon Module manufacturing plant in Hyderabad, Telangana. The balance of the proceeds will be used for general?corporate purposes.
Q3 FY25 results witnessed strong growth. Premier Energies, posted a whopping 490% growth in its consolidated net profit at ?254.9 crore, against ?431.5 crore?in the year-ago period. Consolidated total income also surged over 144% notched at ?17,493.8?million. This is against ?7,147.3 million in the corresponding period last?year. The?profit margin expanded 4.54% in Q3FY25 vis-a-vis the 6.05% reported in Q3FY24.
Premier Energies has over 29 years of expertise in?manufacturing solar cells and modules. The firm has an annual capacity?of 2 GW for solar cells and 4.13 MW for solar modules. It has five manufacturing?facilities.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.